Tobrex Eye Drops, 0.3%, 5 mL in a "Drop-Tainer®" dropper bottle
Composition
Active ingredient: 1 mL of solution contains 3 mg of tobramycin;
Excipients: benzalkonium chloride, boric acid, anhydrous sodium sulfate, sodium chloride, tiloxapol, sulfuric acid and/or sodium hydroxide, purified water.
Dosage Form
Eye drops.
Main physicochemical properties: a clear solution ranging in color from colorless to pale yellow or brown.
Pharmacological group
Agents used in ophthalmology. Antimicrobial agents. Antibiotics. ATX code S01A A12.
Pharmacological properties
Pharmacodynamics.
Tobramycin is a fast-acting bactericidal antibiotic of the aminoglycoside group. Its primary action targets bacterial cells and involves the inhibition of the peptidyl transferase complex and protein synthesis in the ribosomes.
Resistance to tobramycin arises through several different mechanisms, including changes in the ribosomal subunits within the bacterial cell, impaired transport of tobramycin into the cell, and inactivation of tobramycin by a group of adenylating, phosphorylating, and acetylating enzymes. Genetic information regarding the production of inactivating enzymes may be carried on bacterial chromosomes or plasmids. Cross-resistance to other aminoglycosides may occur.
The following threshold values and in vitro activity spectrum are based on systemic administration. These values may not be applicable when the drug is administered topically to the eye, since higher concentrations are achieved with topical administration and local physical/chemical conditions may affect the drug’s activity at the site of administration. According to the European Committee on Antibiotic Susceptibility Testing (EUCAST), the following breakpoints have been established for tobramycin:
Enterobacteriaceae: S ≤ 2 mg/L, R > 4 mg/L,
Pseudomonas spp. S ≤ 4 mg/L, R > 4 mg/L,
Acinetobacter spp. S ≤ 4 mg/L, R > 4 mg/L,
Staphylococcus spp. S ≤ 1 mg/L, R > 1 mg/L,
Non-species-specific: S ≤ 2 mg/L, R > 4 mg/L.
The information below indicates whether microorganisms will be susceptible to tobramycin in TOBREX®. The instructions list only the types of bacteria that commonly cause external eye infections, such as conjunctivitis.
The prevalence of acquired resistance may vary geographically and over time for the relevant microorganism species; therefore, it is advisable to have local information on microorganism resistance, especially when treating severe infections. If necessary, consult a specialist if the local prevalence of resistance is such that the efficacy of tobramycin, at least against certain types of infections, is questionable.
| Susceptible Species |
| Aerobic Gram-positive microorganisms |
| Bacillus megaterium |
| Bacillus pumilus |
| Corynebacterium accolens |
| Corynebacterium bovis |
| Corynebacterium macginleyi |
| Corynebacterium pseudodiphtheriticum |
| Kocuria kristinae |
| Staphylococcus aureus (methicillin-sensitive) |
| Staphylococcus haemolyticus (methicillin-sensitive). |
| Aerobic Gram-negative microorganisms |
| Acinetobacter junii |
| Acinetobacter ursingii |
| Citrobacter koseri |
| Escherichia coli |
| Klebsiella oxytoca |
| Klebsiella pneumoniae |
| Moraxella catarrhalis |
| Moraxella oslonensis |
| Morganella morganii |
| Neisseria perflava |
| Proteus mirabilis |
| Pseudomonas aeruginosa |
| Serratia liquifaciens. |
| Conditionally resistant species |
| Acinetobacter baumanii |
| Bacillus cereus |
| Bacillus thuringiensis |
| Kocuria rhizophila |
| Staphylococcus aureus (methicillin-resistant) |
| Staphylococcus epidermidis |
| Staphylococcus haemolyticus (methicillin-resistant)* |
| Staphylococcus, other coagulase-negative species |
| Serratia marcescens. |
| Resistant microorganisms |
| Aerobic Gram-positive microorganisms |
| Enterococcus faecalis |
| Streptococcus mitis |
| Streptococcus pneumoniae |
| Streptococcus pyogenes |
| Streptococcus sanguis. |
| Aerobic Gram-negative microorganisms |
| Chryseobacterium indologenes |
| Haemophilus influenzae |
| Stenotrophomonas maltophilia |
| Anaerobic bacteria |
| Propionibacterium acnes. |
*Resistance rates exceed 50%.
Preclinical safety data
Data on systemic toxicity are well established. The systemic effects of tobramycin at toxic doses significantly exceeding the dose used for topical ocular application may be associated with nephrotoxicity and ototoxicity.
In vitro and in vivo studies of tobramycin did not reveal any mutagenic effects.
Tobramycin crosses the placenta into the fetal circulation and amniotic fluid. Animal studies involving systemic administration of high doses of tobramycin to pregnant animals during organogenesis revealed renal toxicity and ototoxicity in the fetus. Other studies conducted in rats and rabbits involving parenteral administration of tobramycin at doses exceeding 100 mg/kg/day (>400 times the maximum clinical dose) did not reveal any cases of impaired fertility or adverse effects on the fetus.
No studies have been conducted to evaluate the carcinogenic potential of tobramycin.
Children
More than 600 children were enrolled in 10 clinical studies of tobramycin eye drops or eye ointment for the treatment of bacterial conjunctivitis, blepharitis, or blepharoconjunctivitis. The patients’ ages ranged from 1 to 18 years. Overall, the safety profile in children was comparable to that in adult patients. No dosage recommendations can be made for children under 1 year of age due to insufficient data.
Pharmacokinetics.
The systemic exposure to tobramycin following topical ophthalmic administration of TOBREX® eye drops is low. Plasma tobramycin concentrations were not quantified in 9 of 12 patients who used an ophthalmic suspension containing 0.3% tobramycin and 0.1% dexamethasone, in each eye 4 times daily for two consecutive days. The highest detected level was 0.25 μg/mL, which is 8 times lower than the concentration of 2 μg/mL, known to be below the threshold for the risk of nephrotoxicity.
Tobramycin is rapidly and extensively excreted in the urine via glomerular filtration, primarily in an unchanged form. The half-life in plasma is approximately 2 hours, with a clearance of 0.04 L/hour/kg and a volume of distribution of 0.26 L/kg. Plasma protein binding is negligible, less than 10%. Bioavailability following oral administration of tobramycin is low (<1%).
Children
TOBREX® may be used in children over 1 year of age at the same dose as in adults. Information regarding use in children under 1 year of age is limited.
Indications
Treatment of external infections of the eye and adjacent tissues caused by pathogenic microorganisms susceptible to tobramycin.
Contraindications
Hypersensitivity to the active ingredient or to any of the drug’s excipients.
Drug Interactions and Other Interactions
Concomitant use of corticosteroids and tobramycin at a concentration of 3 mg/mL may mask the clinical signs of bacterial, fungal, or viral infections and suppress hypersensitivity reactions.
Interactions with other medications have been reported following systemic administration of tobramycin. However, systemic absorption of tobramycin following topical application is so low that the risk of any interaction is minimal.
If multiple topical ophthalmic medications are used simultaneously, an interval of at least 10–15 minutes should be observed between applications. Eye ointments should be applied last.
Special Instructions for Use
- For topical ophthalmic use only. Not intended for injection or oral administration.
- After opening the bottle for the first time, remove the tamper-evident ring.
- Some patients may develop sensitivity to topically applied aminoglycosides. The severity of hypersensitivity reactions may range from local effects to generalized reactions, such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If hypersensitivity occurs during treatment with this drug, its use should be discontinued, as should the use of other medications being taken (see the “Adverse Reactions” section).
- Cross-hypersensitivity to other aminoglycosides may occur; it should also be noted that patients who become hypersensitive to tobramycin administered topically to the eye may also become hypersensitive to other topically and/or systemically administered aminoglycosides.
- Serious adverse reactions, including neurotoxicity, ototoxicity, and nephrotoxicity, have occurred in patients receiving tobramycin as systemic therapy. Caution is recommended when tobramycin is used concomitantly with topical and systemic aminoglycosides; total serum aminoglycoside concentrations should be monitored (see the “Adverse Reactions” section).
- Caution should be exercised when prescribing TOBREX® to patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease. Aminoglycosides may exacerbate muscle weakness due to their potential effect on neuromuscular function.
- As with other antibiotics, prolonged use of TOBREX® may lead to overgrowth of non-susceptible microorganisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.
- Wearing contact lenses is not recommended during treatment for infectious eye diseases. Therefore, patients are advised not to wear contact lenses while being treated with this medication.
- TOBREX®, eye drops, contain benzalkonium chloride, which may cause irritation and is known to discolor soft contact lenses. Contact with soft contact lenses should be avoided. If patients are permitted to wear contact lenses, they should be informed that they must remove their contact lenses before using TOBREX® and wait 15 minutes after instillation before reinserting them.
- To prevent contamination of the dropper tip and the solution, take care not to touch the eyelids, surrounding areas, or other surfaces with the tip of the dropper bottle.
Use During Pregnancy or Breastfeeding.
Reproductive function
No studies have been conducted on the effects of tobramycin on human or animal reproductive function following topical application (see the “Pharmacological Properties” section).
Pregnancy
There are no or very limited data on the topical use of tobramycin in the eyes of pregnant women. Studies involving volunteers have not revealed a link between the use of tobramycin and developmental defects. When administered to pregnant women, tobramycin crosses the placenta and reaches the fetus. When exposed in utero, tobramycin does not cause ototoxicity.
Animal studies have demonstrated toxic effects on reproductive function at doses exceeding the maximum permitted dose for humans; therefore, these data have limited clinical significance (see the “Pharmacological Properties” section).
Although the systemic effects of tobramycin following topical application are expected to be minimal, as a precaution, it is best to avoid using tobramycin during pregnancy. TOBREX® may be used by women planning to become pregnant. TOBREX® is not recommended for use during pregnancy.
Lactation
Minimal exposure to tobramycin in breast milk has been detected following intravenous or intramuscular administration of up to 150 mg of tobramycin three times daily. Although there are no specific data regarding systemic exposure to tobramycin following ophthalmic use, given the much lower doses of the drug administered topically to the eyes compared to the systemic doses mentioned above, even with minimal transfer into breast milk, no adverse effects are expected when breastfeeding a newborn or infant. Topical ophthalmic use of tobramycin is permissible during breastfeeding if the benefit of the drug to the mother outweighs the risk to the newborn/infant being breastfed.
Effect on reaction time when driving or operating machinery.
The effect of TOBREX® on the ability to drive or operate machinery is nonexistent or negligible. Temporary blurred vision or other visual disturbances may affect the ability to drive or operate machinery. If blurred vision occurs while instilling the eye drops, the patient should wait until vision clears before driving or operating machinery.
Dosage and Administration
As with other antibiotics, appropriate monitoring of bacterial susceptibility to the drug should be conducted.
Use in adults, including elderly patients.
For mild to moderate disease, instill 1–2 drops into the conjunctival sac(s) of the affected eye(s) every 4 hours.
For severe cases, instill 1–2 drops into the conjunctival sac(s) of the affected eye(s) every hour until improvement is observed; the frequency of administration should be gradually reduced until treatment is discontinued.
Treatment usually lasts 7–10 days.
After instillation, it is recommended to gently close the eyelids or apply pressure to the nasolacrimal duct. This reduces systemic absorption of the medication instilled into the eye, thereby lowering the likelihood of systemic side effects.
When using other topical ophthalmic medications concurrently, a 10–15-minute interval should be observed between applications.
Patients with impaired liver or kidney function.
There are no data from studies on the use of TOBREX® in this patient population. However, due to the low systemic absorption of tobramycin when the drug is used topically, no dose adjustment is necessary.
Children.
TOBREX® eye drops may be used in children aged 1 year and older at the same dose as in adults. The available data are described in the “Pharmacological Properties” section. The safety and efficacy of TOBREX® eye drops for children under 1 year of age have not been established.
Overdose
No toxic effects are expected in the event of an overdose following topical application of the drug or accidental ingestion of the contents of 1 vial, given the characteristics of this drug.
Possible clinical signs and symptoms of an overdose with TOBREX® (punctate keratitis, erythema, increased tearing, swelling, and itching of the eyelids) may be similar to the adverse reactions observed in some patients.
In the event of an overdose following topical application, any excess TOBREX® should be rinsed from the eye(s) with warm water.
Side Effects
During clinical trials, the most common adverse reactions were eye redness and a sensation of eye discomfort, which occurred in approximately 1.4% and 2% of patients, respectively. The following adverse reactions were observed during clinical trials of TOBREX and were classified by frequency as follows: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), isolated cases (≥1/10,000, <1/1,000), and rare (<1/10,000). Within each group, adverse reactions are listed in order of decreasing severity.
| Organ systems | Adverse Reactions
[According to MedDRA (version 15.1)] |
| Immune system | Uncommon: hypersensitivity. |
| Nervous system | Uncommon: headaches. |
| Eye disorders | Common: eye discomfort, eye redness.
Uncommon: keratitis, corneal abrasion, blurred vision, eye redness, eyelid swelling, conjunctival edema, eye irritation, eye pain, dry eyes, eye discharge, eyelid disorders, itchy eyes, increased tearing. |
| Skin and Subcutaneous Tissue Disorders | Uncommon: urticaria, dermatitis, madarosis, leukoderma, pruritus, dry skin.
|
The following additional adverse reactions were identified during postmarketing surveillance; their incidence cannot be estimated based on available data.
| Organ systems | Adverse reactions
[ According to MedDRA (Version 15.1) ] |
| Immune system | Anaphylactic reaction |
| Eye disorders | Eye allergy, itchy eyelids |
| Skin and subcutaneous tissue disorders | Rash, erythema, Stevens-Johnson syndrome, erythema multiforme. |
Description of Some Adverse Reactions
- Some patients may develop sensitivity to topically applied aminoglycosides (see the “Special Considerations” section).
- Patients who received tobramycin as systemic therapy have experienced serious adverse reactions, including neurotoxicity, ototoxicity, and nephrotoxicity. However, no such reactions have been reported following topical application of tobramycin to the eyes (see the “Special Precautions for Use” section).
- TOBREX® eye drops may be used in children 1 year of age and older at the same dose as adults. The available data are described in the “Pharmacological Properties” section. The safety and efficacy of TOBREX® eye drops for children under 1 year of age have not been established (see the “Dosage and Administration” section).
Shelf Life
3 years.
Shelf life after first opening the bottle: 4 weeks.
Storage Conditions
Store at a temperature not exceeding 25 °C, out of the reach of children. Keep the bottle tightly closed.
Packaging
5 mL per dropper vial; 1 dropper vial per cardboard box.
Manufacturer
Alcon Couvreur.
Address
Rijksweg 14, Puurs-Sint-Amands, 2870, Belgium.
Similar products
Products from the same category









